Nykode Therapeutics AS (VACBF)

Market Cap	55.96M
Revenue (ttm)	8.28M
Net Income (ttm)	-25.32M
Shares Out	n/a
EPS (ttm)	-0.08
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,450
Average Volume	2,716
Open	0.1950
Previous Close	n/a
Day's Range	0.1950 - 0.1950
52-Week Range	0.1927 - 0.9500
Beta	1.17
RSI	14.14
Earnings Date	Aug 27, 2025

About Nykode Therapeutics AS

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of locally advanced and metastatic tumors; and VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 i...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 136
• Stock Exchange: OTCMKTS
• Ticker Symbol: VACBF

Financial Performance

In 2024, Nykode Therapeutics AS's revenue was $9.16 million, a decrease of -31.26% compared to the previous year's $13.32 million. Losses were -$38.82 million, 10.4% more than in 2023.